PMC:7205724 / 508-640
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
17 | 25-28 | Gene | denotes | IL6 | Gene:3569 |
18 | 84-87 | Gene | denotes | IL6 | Gene:3569 |
19 | 52-60 | Species | denotes | patients | Tax:9606 |
20 | 4-15 | Chemical | denotes | Tocilizumab | MESH:C502936 |
21 | 66-74 | Disease | denotes | COVID-19 | MESH:C000657245 |
53 | 103-120 | Species | denotes | novel coronavirus | Tax:2697049 |
54 | 122-131 | Species | denotes | SARS-CoV2 | Tax:2697049 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T5 | 66-74 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 122-126 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T5 | 66-74 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T6 | 122-131 | Species | denotes | SARS-CoV2 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 1-88 | Sentence | denotes | • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6. |
T10 | 90-98 | Sentence | denotes | Abstract |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
20 | 4-15 | Chemical | denotes | Tocilizumab | MESH:C502936 |
17 | 25-28 | Gene | denotes | IL6 | Gene:3569 |
19 | 52-60 | Species | denotes | patients | Tax:9606 |
21 | 66-74 | Disease | denotes | COVID-19 | MESH:C000657245 |
18 | 84-87 | Gene | denotes | IL6 | Gene:3569 |
53 | 103-120 | Species | denotes | novel coronavirus | Tax:2697049 |
54 | 122-131 | Species | denotes | SARS-CoV2 | Tax:2697049 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T45 | 25-28 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
T89 | 84-87 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T75 | 1-2 | IN | denotes | • |
T76 | 4-15 | NNP | denotes | Tocilizumab |
T77 | 15-16 | -COMMA- | denotes | , |
T78 | 17-19 | DT | denotes | an |
T79 | 20-28 | NN | denotes | anti-IL6 |
T80 | 28-29 | -COMMA- | denotes | , |
T81 | 30-33 | MD | denotes | can |
T82 | 34-40 | VB | denotes | confer |
T83 | 41-48 | NN | denotes | benefit |
T84 | 49-51 | IN | denotes | in |
T85 | 52-60 | NNS | denotes | patients |
T86 | 61-65 | IN | denotes | with |
T87 | 66-74 | NN | denotes | COVID-19 |
T88 | 75-78 | CC | denotes | and |
T89 | 79-83 | JJ | denotes | high |
T90 | 84-87 | NN | denotes | IL6 |
T91 | 90-98 | NN | denotes | Abstract |
T92 | 99-102 | DT | denotes | The |
T93 | 103-108 | JJ | denotes | novel |
T94 | 109-120 | NN | denotes | coronavirus |
T95 | 120-121 | -COMMA- | denotes | , |
T96 | 122-131 | NN | denotes | SARS-CoV2 |
T97 | 131-132 | -COMMA- | denotes | , |
R69 | T82 | T75 | arg1Of | confer,• |
R70 | T76 | T77 | arg1Of | Tocilizumab,"," |
R71 | T79 | T77 | arg2Of | anti-IL6,"," |
R72 | T79 | T78 | arg1Of | anti-IL6,an |
R73 | T82 | T80 | arg1Of | confer,"," |
R74 | T76 | T81 | arg1Of | Tocilizumab,can |
R75 | T82 | T81 | arg2Of | confer,can |
R76 | T76 | T82 | arg1Of | Tocilizumab,confer |
R77 | T83 | T82 | arg2Of | benefit,confer |
R78 | T82 | T84 | arg1Of | confer,in |
R79 | T85 | T84 | arg2Of | patients,in |
R80 | T85 | T86 | arg1Of | patients,with |
R81 | T88 | T86 | arg2Of | and,with |
R82 | T87 | T88 | arg1Of | COVID-19,and |
R83 | T90 | T88 | arg2Of | IL6,and |
R84 | T90 | T89 | arg1Of | IL6,high |
R85 | T94 | T92 | arg1Of | coronavirus,The |
R86 | T94 | T93 | arg1Of | coronavirus,novel |
R87 | T94 | T95 | arg1Of | coronavirus,"," |
R88 | T96 | T95 | arg2Of | SARS-CoV2,"," |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T5 | 66-74 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 122-131 | Disease | denotes | SARS-CoV2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 1-88 | Sentence | denotes | • Tocilizumab, an anti-IL6, can confer benefit in patients with COVID-19 and high IL6. |
T10 | 90-98 | Sentence | denotes | Abstract |